As of month 36 (May 2025), no final scientific results are available yet, as the clinical trial has just completed recruitment and remains active until all patients finish the 12-month follow-up. While outcome data is expected after trial completion, the tools developed are fully functional and in use, representing a clear advancement beyond the current state of the art.
Key achievements include:
• The CINDERELLA Integrated Platform, combining BreLo-AI modules with the CANKADO platform.
• The BreLo-AI aesthetic scoring algorithm, case retrieval system, and torso morphing module.
• The BCCT.core extension for aesthetic evaluation.
• The CANKADO eConsent module, enabling digital and compliant patient enrolment.
• A large multicentre imaging and clinical dataset.
• A health technology assessment model to support cost-effectiveness and reimbursement discussions.
• Visual branding and a detailed clinical protocol for reuse in future projects.
The CINDERELLA Consortium has defined a clear go-to-market strategy combining public funding and private sector engagement. The primary path is submission to the European Innovation Council (EIC) Transition program, building on the project’s strong clinical, technical, and regulatory foundations. This funding would support product optimisation, targeted validation, and CE certification as a digital medical device, enabling faster European market entry while ensuring patient safety and compliance with MDR. In parallel, discussions with investors, philanthropic organisations, and industry partners are underway to secure complementary funding. This dual-track approach reflects growing market interest, safeguards clinical and commercial potential, and reduces risks in the transition from research to market, ensuring timely and scalable patient access.
